Browse
Submit Data
Databases
API
Help

Dataset Information

14 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Phase II study of chemotherapy with UFT/LV/Bevacizumab in elderly patients with advanced and recurrent colorectal cancer.

ABSTRACT: Interventions: UFT 300mg/m2/day and LV 50mg/body/day is administered orally for 21 days every 28 days. Bevacizumab 5mg/kg is administered intravenous injection on day 1,15. Primary outcome(s): Overall response rate Study Design: Single arm Non-randomized

DISEASE(S): Advanced And Recurrent Colorectal Cancer

PROVIDER: 2618906 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Phase II study of bevacizumab combined with oral leucovorin plus UFT for elderly patients with metastatic colorectal cancer.

Project description:Interventions: Bevacizumab 5mg/kg is administered intravenous injection on day 1,15. UFT 300mg/m2/day and LV 75mg/body/day is administered orally for 21 days every 28 days. Primary outcome(s): Progression-free survival Study Design: Single arm Non-randomized

| 2618974 | ecrin-mdr-crc

Phase II study of first line chemotherapy with UFT/LV in elderly patients with advanced/recurrent colorectal cancer.

Project description:Interventions: UFT 300mg/m2/day and LV 75mg/body/day is administered orally for 28 days every 35 days. Primary outcome(s): response rate Study Design: Single arm Non-randomized

| 2622557 | ecrin-mdr-crc

A randomized phase II study of UFT/LV or TEGAFOX for patient with curatively resected high risk Stage II and Stage III colorectal cancer.

Project description:Interventions: UFT(300mg/m2)+LV(75mg) /day, orally 4 weeks on and 1 week off in each corse. Total 5 weeks. UFT(300mg/m2)+LV(75mg) /day, orally 4 weeks on and 1 week off in each corse. Total 5 weeks. Oxaliplatin gives 85 mg/m2 intravenously on 1,15 day of each course. Primary outcome(s): 3-year desiese free survival rate Study Design: Parallel Randomized

| 2623111 | ecrin-mdr-crc

Clinical trial on the QOL of the Tegafur/Uracil plus Leucovolin(UFT/LV) to adjuvant chemotherapy for the Stage II, III colorectal cancer

Project description:Interventions: Tegafur/uracil with oral leucovorin(UFT/LV) UFT is administered orally at 300mg/m2/day with 75mg/day of oral leucovorin for 21 consecutive days followed by a 7 days rest. Primary outcome(s): Quality of Life Study Design: Single arm Non-randomized

| 2624363 | ecrin-mdr-crc

A feasibility study of adjuvant therapy with UFT/LV plus oxaliplatin following curative resection for stage III colorectal cancer

Project description:Interventions: UFT 300mg per m2 per day and LV 75mg per day for 28 days Oxaliplatin:85mg/m2 day1,15 every 5-weeks for 3-cycle After this therapy, followed by UFT/LV until 1 year Primary outcome(s): Patients ratio with completion of adjuvant TEGAFOX therapy Study Design: Single arm Non-randomized

| 2618840 | ecrin-mdr-crc

A randomized phase II trial of adjuvant chemotherapy with UFT/LV versus S-1 following curative resection for stage III colorectal cancer

Project description:Interventions: UFT 300mg per m2 per day and LV 75mg per day for 28 days every 5-weeks for 6 months TS-1 80mg per m2 per day for 28 days every 6-weeks for 12 months Primary outcome(s): 3-year disease free survival rate Study Design: Parallel Randomized

| 2617052 | ecrin-mdr-crc

A Randomized Trial of Adjuvant Chemotherapy with UFT / LV versus PSK / UFT / LV following curative resection for Stage II / III Colorectal Cancer

Project description:Interventions: Group A (standard therapy group:UFT/LV 6M): Administration of 5 courses (6 months) of a schedule in which one course consists of UFT (300 mg/m2/day) and LV (75 mg/day) for 28 consecutive days followed by 7 days off the drugs. Group B (trial therapy group: PSK/UFT/LV 6M): Administration of 5 courses (6 months) of a schedule in which one course consists of UFT (300 mg/m2/day) and LV (75 mg/day) for 28 consecutive days followed by 7 days off the drugs. And administration of every day PSK (3g/body) for 6 months. Group C (trial therapy group: PSK/UFT/LV 12M): Administration of 10 courses (12 months) of a schedule in which one course consists of UFT (300 mg/m2/day) and LV (75 mg/day) for 28 consecutive days followed by 7 days off the drugs. And administration of every day PSK (3g/body) for 12 months. Primary outcome(s): 3 year desease free survival rate Study Design: Parallel Randomized

| 2620921 | ecrin-mdr-crc

3`mRNA sequencing of liver RNA (MACE) at the 30h time point after acetaminophen (APAP) 300mg/kg administration

Project description:Hepatic RNA from mice (C57BL/6) of 2 groups (APAP-treated (300mg/kg), n=8; APAP (300mg/kg)-AZD7986 (5mg/kg), n=8) were pooled at equal shares. Thereafter, pooled RNA underwent analysis by 3`mRNA sequencing (MACE, GenXPro, Frankfurt, Germany)

2024-06-26 | GSE263673 | GEO

A feasibility study of adjuvant therapy with UFT/Leucovorin+Oxaliplatin following curative resection for stage III colorectal cancer

Project description:Interventions: UFT 300mg per m2 per day and LV 75mg per day for 28 days Oxaliplatin:85mg/m2 day1,15 every 35 days for 5-cycle Primary outcome(s): Treatment completion ratio Study Design: Single arm Non-randomized

| 2631332 | ecrin-mdr-crc

SOAC-1101

| 2614185 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data